Docetaxel (Taxotere) in hormone-refractory prostate cancer

被引：0
|
作者：
Petrylak, DP [1 ]
机构：
[1] Columbia Univ Coll Phys & Surg, Columbia Presbyterian Med Ctr, Div Med Oncol, New York, NY 10032 USA
来源：
SEMINARS IN ONCOLOGY | 2000年 / 27卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 29
页数：6
相关论文
共 50 条
  • [31] Mitotic catastrophe and apoptosis induced by Docetaxel in hormone-refractory prostate cancer cells
    Fabbri, Francesco
    Amadori, Dino
    Carloni, Silvia
    Brigliadori, Giovanni
    Tesei, Anna
    Ulivi, Paola
    Rosetti, Marco
    Vannini, Ivan
    Arienti, Chiara
    Zoli, Wainer
    Silvestrini, Rosella
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2008, 217 (02) : 494 - 501
  • [32] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    [J]. Investigational New Drugs, 2008, 26 : 75 - 79
  • [33] Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer
    Matsumoto, Akihiro
    Inoue, Atsushi
    Yokoi, Satoshi
    Nozumi, Kazuyoshi
    Miyazaki, Kanetaka
    Hosoki, Shigeru
    Nagata, Maki
    Yamaguchi, Kunio
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (08) : 687 - 691
  • [34] Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel
    Sallah, S
    Gagnon, GA
    [J]. CANCER INVESTIGATION, 2000, 18 (03) : 191 - 196
  • [35] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Younis, Islam R.
    George, Daniel J.
    McManus, Terence J.
    Hurwitz, Herbert
    Creel, Patricia
    Armstrong, Andrew J.
    Yu, Jing Jie
    Bacon, Kristina
    Hobbs, Gerald
    Peer, Cody J.
    Petros, William P.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 991 - 997
  • [36] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Norihito Soga
    Manabu Kato
    Kouhei Nishikawa
    Yoshihiro Hasegawa
    Yasushi Yamada
    Hideaki Kise
    Kiminobu Arima
    Yoshiki Sugimura
    [J]. International Journal of Clinical Oncology, 2009, 14 : 130 - 135
  • [37] Second-line navelbine plus estramustine after taxotere in hormone-refractory prostate cancer
    Perroni, D.
    Paze, E.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 69 - 69
  • [38] Taxanes in hormone-refractory prostate cancer
    Kang, MH
    Figg, WD
    Dahut, W
    [J]. CANCER PRACTICE, 1999, 7 (05) : 270 - 272
  • [39] Chemotherapy of the hormone-refractory prostate cancer
    Heine, K
    Wolff, JM
    [J]. AKTUELLE UROLOGIE, 2004, 35 (03) : 209 - 214
  • [40] Management of hormone-refractory prostate cancer
    Dogliotti, L
    Mosca, A
    [J]. TUMORI, 2003, : S147 - S149
12345